Electroclinical features of epilepsy in AUTS2-related syndrome: case description and narrative review.

SeizureJul 29, 2026 (epub)
Case ReportNeurologyMedical Genetics

Gaetano Maria Celardo, Matilde Neri, Gemma Marinella et al.

✦ AI-curated · Sources linked

Case in brief

A patient with AUTS2-related syndrome presented with epilepsy characterized by developmental/epileptic encephalopathy and spike-wave activation during sleep. The case emphasizes the need for thorough electroclinical evaluation to understand the epilepsy's features and outcomes better. Systematic EEG and cognitive monitoring were recommended to enhance clinical management.

Diagnostic / clinical pearl

Clinicians should recognize that epilepsy in AUTS2-related syndrome can present as developmental/epileptic encephalopathy with specific electroclinical features.

Why it matters

This case underscores the necessity for comprehensive monitoring of electroclinical features in patients with AUTS2-related syndrome to optimize management strategies.

Source

PubMed · PMID 42541981

Published in Seizure. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.